文献速递前列腺癌

经直肠与经会阴前列腺活检后临床显著前列腺癌检出:前列腺活检有效性及并发症随机临床试验结果

Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
PubMed 文献 · J Urol · 2024-05-03

该随机临床试验纳入840例男性,其中384例接受经直肠活检、398例接受经会阴活检,比较两种途径对临床显著前列腺癌(Grade Group≥2)的检出率。经直肠与经会阴活检的临床显著前列腺癌检出率分别为47.1%和43.2%(OR 1.17;95%CI 0.88-1.55),差异无统计学意义。作者结论为两种活检方式在检出临床显著前列腺癌方面无显著差异,泌尿外科医生可根据患者需求和实践环境选择任一活检方式。

要点

  • 经直肠与经会阴活检的临床显著前列腺癌检出率分别为47.1%与43.2%(OR 1.17;95%CI 0.88-1.55),差异无统计学意义。
  • 年龄、PSA密度、临床分期和PI-RADS评分与临床显著前列腺癌诊断相关,既往活检史、前部肿瘤和活检途径不相关。
  • 在未活检过的男性中,MRI靶向经直肠与经会阴活检的临床显著前列腺癌检出率分别为59%与62%。

核心结论

  • 经直肠与经会阴前列腺活检在临床显著前列腺癌检出方面未见显著差异。
  • 作者认为泌尿外科医生可根据患者需求与实践环境选择任一活检方式。

研究设计与样本

  • 随机临床试验,共随机840例男性,其中384例接受经直肠活检、398例接受经会阴活检。
  • 93%为白人,44%有既往活检史,中位年龄66岁,中位PSA密度0.14,96%的男性活检前接受前列腺MRI。
  • 以Grade Group≥2前列腺癌定义为临床显著前列腺癌,采用逻辑回归计算比值比评估活检方式对癌症检出率的影响。

主要发现

  • 经直肠与经会阴活检的临床显著前列腺癌检出率分别为47.1%与43.2%(OR 1.17;95%CI 0.88-1.55)。
  • 年龄、PSA密度、临床分期和前列腺影像报告和数据系统评分与临床显著前列腺癌诊断相关,既往活检史、前部肿瘤和活检途径(经直肠或经会阴)不相关。
  • 在未活检过的男性中,接受MRI靶向经直肠或经会阴活检的临床显著前列腺癌检出率分别为59%与62%。
  • 经直肠与经会阴活检的总体癌症检出率分别为72.1%与70.4%。

关键数值与推荐

  • 临床显著前列腺癌定义为Grade Group≥2前列腺癌。

临床怎么用

  • 作者认为泌尿外科医生可根据患者需求与实践环境选择任一活检方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The comparative effectiveness of transrectal and transperineal prostate biopsy in detecting clinically significant prostate cancer is not well understood. We conducted a randomized clinical trial to determine whether transperineal biopsy improves the detection of clinically significant prostate cancer. MATERIALS AND METHODS: Of the 840 men randomized, 93% were White, 44% had a previous biopsy, with a median age of 66 years and median PSA density of 0.14. Of these, 384 underwent transrectal and 398 underwent transperineal prostate biopsy. Prebiopsy prostate MRI was performed in 96% of men. Grade Group ≥ 2 prostate cancer was classified as clinically significant. Odds ratios were calculated using logistic regression to evaluate the effect of biopsy procedures on cancer detection rates. RESULTS: The detection rates of clinically significant prostate cancer were 47.1% and 43.2% (odds ratio 1.17; 95% CI, 0.88-1.55) for transrectal and transperineal biopsy, respectively. Age, PSA density, clinical stage and Prostate Imaging Reporting and Data System score were associated with the diagnosis of clinically significant cancer, whereas history of previous biopsy, anterior tumors, and biopsy procedure (transrectal or transperineal) were not. Clinically significant cancer detection rates in biopsy-naïve men undergoing MRI-targeted transrectal or transperineal biopsy were 59% and 62%, respectively. The overall cancer detection rates following transrectal and transperineal biopsy were 72.1% and 70.4%, respectively. CONCLUSIONS: There was no significant difference noted in the detection of clinically significant prostate cancer following transrectal or transperineal prostate biopsy. Urologists may utilize either biopsy procedure that best suits their patients' needs and practice setting.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mian BM, Feustel PJ, Aziz A, et al. Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial. J Urol. 2024. PMID: 38700844. doi:10.1097/JU.0000000000003979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。